ResearcherCharles UniversityActive in the last 2 years
Igor Sirák
Matched on ORCID iD 0000-0002-5972-3866; OpenAlex author ID A5043931261. Sources: OpenAlex.
Their work
- Papers
- 2 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 5
2024: 1 paper · 2025: 1 paper
Papers 2
- Long-term aspirin use influences the probability of distant metastases and operability in patients with pancreatic ductal adenocarcinoma: a single-center retro… Last author DOI 10.5603/rpor.104017↗
- Stereotactic Radiotherapy Plus Nivolumab in Patients with Locally Advanced Pancreatic Cancer: Results from Phase 1/2 Clinical CA209-9KH Trial. Last author DOI 10.1007/s40487-024-00309-z↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Aml Mustafa Banni · 2 shared papers, 2024–2025 · strength 0.48
- Paper Long-term aspirin use influences the probability of distant metastases and operability in patients with pancreatic duct… DOI 10.5603/rpor.104017↗
- Paper Stereotactic Radiotherapy Plus Nivolumab in Patients with Locally Advanced Pancreatic Cancer: Results from Phase 1/2 Cl… DOI 10.1007/s40487-024-00309-z↗
- Milan Vošmik · 2 shared papers, 2024–2025 · strength 0.48
- Paper Long-term aspirin use influences the probability of distant metastases and operability in patients with pancreatic duct… DOI 10.5603/rpor.104017↗
- Paper Stereotactic Radiotherapy Plus Nivolumab in Patients with Locally Advanced Pancreatic Cancer: Results from Phase 1/2 Cl… DOI 10.1007/s40487-024-00309-z↗
- Josef Dvořák · 1 shared paper, 2024 · strength 0.21
- Bohuslav Melichar · 1 shared paper, 2024 · strength 0.21
- Beatrice Mohelníková-Duchoňová · 1 shared paper, 2024 · strength 0.21
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.